Jefferies analyst Roger Song raised the firm’s price target on Nektar (NKTR) to $69 from $2 and keeps a Buy rating on the shares after the company’s REZOLVE-AD study of investigational rezpegaldesleukin met all endpoints. This data update gives Jefferies further confidence in Rezpeg’s potential as a novel biologic with a strong efficacy and safety profile in an enormous disease space, the firm told investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar price target raised to $100 from $60 at BTIG
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data
- Nektar price target raised to $120 from $6.50 at H.C. Wainwright
- Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today?